Полиморбидный пациент: в фокусе гастроэзофагеальная рефлюксная болезнь

2. Lovell M. Caring for the elderly: Changing perceptions and attitudes. J Vasc Nursing 2006; 24 (1): 22–6.
3. Арутюнов А.Г., Бурков С.Г. Гастроэзофагеальная рефлюксная болезнь у пациентов пожилого и старческого возраста. Клин. перспективы гастроэнтерологии, гепатологии. 2005; 1: 31–8. / Arutyunov A.G., Burkov S.G. Gastroezofageal'naya reflyuksnaya bolezn' u patsientov pozhilogo i starcheskogo vozrasta. Klin. perspektivy gastroenterologii, gepatologii. 2005; 1: 31–8. [in Russian]
4. Ивашкин В.Т. Рациональная фармакотерапия заболеваний органов пищеварения. М.: Литтерра, 2003. / Ivashkin V.T. Racionalnaya farmakoterapiya zabolevanij organov pishevareniya. M.: Litterra, 2003. [in Russian]
5. Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide bethanechol. Gastroenterology 1980.
6. Bytzer P, Talley NJ, Leemon M et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15.000 adults. Arch Intern Med 2001.
7. Camilleri M, Magelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest 1984.
8. Chang ЕВ, Fedorak RN, Field M. Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterology 1986; 91 (3).
9. Dyck PJ, Thomas PK. Diabetic Neuropathy.
10. Dyrberg T. Prevalence of diabetic autonomic neuropathy measured by simple bedside tests.
11. Sandu M, Barboi О, Drug V et al. Gastroesophageal reflux disease in respiratory disorders. J Gastroenterol Hepatol 2013; 28 (Suppl. 31): 513.
12. Губергриц Н.Б., Крюк Н.А. Особенности лечения больных хроническим панкреатитом в сочетании с гастроэзофагеальной рефлюксной болезнью. Гастроэнтерология Санкт-Петербурга. 2007; 1–2: 114. / Gubergric N.B., Kryuk N.A. Osobennosti lecheniya bolnyh hronicheskim pankreatitom v sochetanii s gastroezofagealnoj reflyuksnoj boleznyu. Gastroenterologiya Sankt-Peterburga. 2007; 1–2: 114. [in Russian]
13. Васильев Ю.В., Машарова А.А., Янова О.Б. Гастроэзофагеальная рефлюксная болезнь, сочетающаяся с хроническим панкреатитом и язвенной болезнью. Клинико-эпидемиологические и этно-экологические проблемы заболеваний органов пищеварения. Красноярск, 2005; с. 18–9. / Vasilev Yu.V., Masharova A.A., Yanova O.B. Gastroezofagealnaya reflyuksnaya bolezn, sochetayushayasya s hronicheskim pankreatitom i yazvennoj boleznyu. Kliniko-epidemiologicheskie i etno-ekologicheskie problemy zabolevanij organov pishevareniya. Krasnoyarsk, 2005; s. 18–9. [in Russian]
14. Xuan Jiang, Yan H, Peng X et al. Study on the characteristics of gastroesopheal reflux disease overlap with functional bowl diseases in Gl clinic. J Gastroenterol Hepatol 2013; 28 (Suppl. 3): 511.
15. Сторонова О.А., Трухманов А.С., Драпкина О.М., Ивашкин В.Т. Эзофагогенные и коронарогенные боли в грудной клетке: проблемы дифференциальной диагностики. Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2002; 12 (1): 68–73. / Storonova O.A., Truhmanov A.S., Drapkina O.M., Ivashkin V.T. Ezofagogennye i koronarogennye boli v grudnoj kletke: problemy differencialnoj diagnostiki. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2002; 12 (1): 68–73. [in Russian]
16. Суханова Т.К., Ивахненко О.М., Ковалева Н.А. Экстрапищеводные бронхопульмональные проявления гастроэзофагеальной рефлюксной болезни. Здравоохранение Дальнего Востока. 2002; 1: 280–9. / Suhanova T.K., Ivahnenko O.M., Kovaleva N.A. Ekstrapishevodnye bronhopulmonalnye proyavleniya gastroezofagealnoj reflyuksnoj bolezni. Zdravoohranenie Dalnego Vostoka. 2002; 1: 280–9. [in Russian]
17. Калягин А.Н. Кардиалгический Х-синдром. Сибирский мед. журн. (Иркутск). 2001; 25 (2): 9–14. / Kalyagin A.N. Kardialgicheskij H-sindrom. Sibirskij med. zhurn. (Irkutsk). 2001; 25 (2): 9–14. [in Russian]
18. Сторонова О.А., Трухманов А.С., Драпкина О.М., Ивашкин В.Т. Эзофагогенные и коронарогенные боли в грудной клетке: проблемы дифференциальной диагностики. Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2002; 12 (1): 68–73. / Storonova O.A., Truhmanov A.S., Drapkina O.M., Ivashkin V.T. Ezofagogennye i koronarogennye boli v grudnoj kletke: problemy differencialnoj diagnostiki. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2002; 12 (1): 68–73. [in Russian]
19. Borjesson M, Albertsson P, Dellborg M et al. Esophageal dysfunction in Syndrome X. Am J Cardiol 1998; 82: 1187–92.
20. Улабидин З., Ивашкин В.Т., Шептулин А.А. и др. Значение суточного мониторирования внутрипищеводного рН в диагностике гастроэзофагеальной рефлюксной болезни и оценке эффективности лекарственных препаратов. Клин. медицина. 1999; 7: 39. / Ulabidin Z., Ivashkin V.T., Sheptulin A.A. i dr. Znachenie sutochnogo monitorirovaniya vnutripishevodnogo rN v diagnostike gastroezofagealnoj reflyuksnoj bolezni i ocenke effektivnosti lekarstvennyh preparatov. Klin. medicina. 1999; 7: 39. [in Russian]
21. Трухманов A.C., Джахая Н.Л., Кайбышева В.О., Сторонова О.А. Новые аспекты рекомендаций по лечению больных гастроэзофагеальной рефлюксной болезнью. Гастроэнтерология и гепатология. 2013; 2: 2–9. / Truhmanov A.C., Dzhahaya N.L., Kajbysheva V.O., Storonova O.A. Novye aspekty rekomendacij po lecheniyu bolnyh gastroezofagealnoj reflyuksnoj boleznyu. Gastroenterologiya i gepatologiya. 2013; 2: 2–9. [in Russian]
22. Hershcovici Т, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs 2011; 71 (18): 2381–9.
23. Бордин Д.С., Колбасников С.В. Патогенетические основы развития гастроэзофагеальной рефлюксной болезни. Диагностика и лечение. Вестн. семейной медицины. 2013; 1: 30–4. / Bordin D.S., Kolbasnikov S.V. Patogeneticheskie osnovy razvitiya gastroezofagealnoj reflyuksnoj bolezni. Diagnostika i lechenie. Vestn. semejnoj mediciny. 2013; 1: 30–4. [in Russian]
24. Kircheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors –comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19–31.
25. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18 (6): 721–7.
26. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 27 (8): 111–4. DOI: 10.2147/ PGPM.S78986
27. Ивашкин В.Т., Маев И.В., Ивашкин К.В. и др. Роль нарушения защитных факторов в развитии кислотозависимых заболеваний (резолюция Экспертного совета 12–13 марта 2016 г.). Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2016; 26 (3): 115. / Ivashkin V.T., Maev I.V., Ivashkin K.V. i dr. Rol narusheniya zashitnyh faktorov v razvitii kislotozavisimyh zabolevanij (rezolyuciya Ekspertnogo soveta 12–13 marta 2016 g.). Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2016; 26 (3): 115. [in Russian]
28. Skoczylas T, Sarosiek I, Sostarich S et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders. Dig Dis Sci 2003; 48: 322–8.
29. Takiuchi H, Asada S, Umegaki E et al. Effects of proton pump inhibitors: omeprazole, lansoprazole, and E-3810 on the gastric mucin. 1994 (abstract).
30. Jaworski T, Sarosiek I, Sostarich S et al. Facg Restorative Impact of Rabeprazole on Gastric Mucus and Mucin Production Impairment During Naproxen Administration. Its Potent Clin Signific Digest Dis Sci 2005; 50 (2): 357–65.
31. Sarosiek I, Olyaee M, Majewski M et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci 2009; 54: 2137–42.
32. Okazaki M, Shimizu I, Ishikawa M et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. J Med Invest 2007; 54 (1–2): 83–90. DOI: 10.2152/jmi.54.83
33. Watanabe T, Higuchi K, Tominaga K et al. Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide: possible involvement of nitric oxide. Drug Exptl Clin Res 2000; 26 (2): 41–5.
34. Ивашкин В.Т., Шептулин А.А., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно-язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Рос. журн. гастроэнтерол., гепатол. и колопроктол. 2014; 6: 89–94. / Ivashkin V.T., Sheptulin A.A., Maev I.V. i dr. Klinicheskie rekomendacii Rossijskoj gastroenterologicheskoj associacii po diagnostike i lecheniyu erozivno-yazvennyh porazhenij zheludka i dvenadcatiperstnoj kishki, vyzvannyh nesteroidnymi protivovospalitelnymi preparatami. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2014; 6: 89–94. [in Russian].
35. Haastrup PF, Paulsen MS, Christensen RD et al. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther 2016; 44 (1): 78–87.
36. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5 (3): 337–44.
37. Lewis PO, Litchfield JM, Tharp JL et al. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors, 2016.
38. Niu Q, Wang Z, Zhang Y et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther 2016; pii: 1074248416663647.
39. Шульпекова Ю.О. применение рабепразола в практике гастроэнтеролога. Мед. совет. Гастроэнтерология. 2016; 14: 26–31. / Shulpekova Yu.O. primenenie rabeprazola v praktike gastroenterologa. Med. sovet. Gastroenterologiya. 2016; 14: 26–31. [in Russian]
40. Irani S, Krevsky B, Desipio J et al. Rapid protection of the gastroduodenal mucosa against aspirininduced damage by rabeprazole. Aliment Pharmacol Ther 2008; 27 (6): 498–503.
41. Карев Е.Н. Рабепразол через призму «метаболизм-эффективность». РМЖ. 2016;
с. 1172–6. / Karev E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost». RMZh. 2016; s. 1172–6. [in Russian]
42. Успенский Ю.П., Пахомова И.Г. Выбор ингибиторов протонной помпы у полиморбидных пациентов. Эксперимент. и клин. гастроэнтерология. 2013; 2: 65–72. / Uspenskij Yu.P., Pahomova I.G. Vybor ingibitorov protonnoj pompy u polimorbidnyh pacientov. Eksperiment. i klin. gastroenterologiya. 2013; 2: 65–72. [in Russian]
43. Звенигородская Л.А., Чурикова А.А. Гастроэзофагеальная рефлюксная болезнь у пожилых больных. РМЖ. 2011; 32: 2084. / Zvenigorodskaya L.A., Churikova A.A. Gastroezofagealnaya reflyuksnaya bolezn u pozhilyh bolnyh. RMZh. 2011; 32: 2084. [in Russian]
44. Осадчук М.А., Свистунов А.А, Осадчук М.М., Николенко Н.Н. Гастроэзофагеальная рефлюксная болезнь как мультидисциплинарная патология. Поликлиника. 2013; 43: 88–96. / Osadchuk M.A., Svistunov A.A, Osadchuk M.M., Nikolenko N.N. Gastroezofagealnaya reflyuksnaya bolezn kak multidisciplinarnaya patologiya. Poliklinika. 2013; 43: 88–96. [in Russian]
45. Еремина Е.Ю. Тактика ведения пациента с гастроэзофагеальной рефлюксной болезнью. РМЖ. 2017; 10: 707–10. / Eremina E.Yu. Taktika vedeniya pacienta s gastroezofagealnoj reflyuksnoj boleznyu. RMZh. 2017; 10: 707–10. [in Russian]
46. Пахомова И.Г. Зиновьева Е.Н. Гастроэзофагеальная рефлюксная болезнь у полиморбидного пациента: особенности терапии. РМЖ. 2017; 10: 760–4. / Pahomova I.G. Zinoveva E.N. Gastroezofagealnaya reflyuksnaya bolezn u polimorbidnogo pacienta: osobennosti terapii. RMZh. 2017; 10: 760–4. [in Russian]
47. Хлынов И.Б., Чикунова М.В. Значение слизисто-бикарбонатного барьера желудка при кислотозависимых заболеваниях. РМЖ 2016; 17: 1125–9. / Hlynov I.B., Chikunova M.V. Znachenie slizisto-bikarbonatnogo barera zheludka pri kislotozavisimyh zabolevaniyah. RMZh 2016; 17: 1125–9. [in Russian]
48. Фадеенко Г.Д. Внепищеводные проявления гастроэзофагеальной рефлюксной болезни. Здоров’я України. 2006; 9: 26–7. / Fadeenko G.D. Vnepishevodnye proyavleniya gastroezofagealnoj reflyuksnoj bolezni. Zdorov’ya Ukrayini. 2006; 9: 26–7. [in Russian]

________________________________________________

1. Lazebnik L.B. Polimorbidnost u pozhilyh. Serdce. 2007; 7: 25–7. [in Russian]
2. Lovell M. Caring for the elderly: Changing perceptions and attitudes. J Vasc Nursing 2006; 24 (1): 22–6.
3. Arutyunov A.G., Burkov S.G. Gastroezofageal'naya reflyuksnaya bolezn' u patsientov pozhilogo i starcheskogo vozrasta. Klin. perspektivy gastroenterologii, gepatologii. 2005; 1: 31–8. [in Russian]
4. Ivashkin V.T. Racionalnaya farmakoterapiya zabolevanij organov pishevareniya. M.: Litterra, 2003. [in Russian]
5. Malagelada JR, Rees WD, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide bethanechol. Gastroenterology 1980.
6. Bytzer P, Talley NJ, Leemon M et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15.000 adults. Arch Intern Med 2001.
7. Camilleri M, Magelada JR. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest 1984.
8. Chang ЕВ, Fedorak RN, Field M. Experimental diabetic diarrhea in rats. Intestinal mucosal denervation hypersensitivity and treatment with clonidine. Gastroenterology 1986; 91 (3).
9. Dyck PJ, Thomas PK. Diabetic Neuropathy.
10. Dyrberg T. Prevalence of diabetic autonomic neuropathy measured by simple bedside tests.
11. Sandu M, Barboi О, Drug V et al. Gastroesophageal reflux disease in respiratory disorders. J Gastroenterol Hepatol 2013; 28 (Suppl. 31): 513.
12. Gubergric N.B., Kryuk N.A. Osobennosti lecheniya bolnyh hronicheskim pankreatitom v sochetanii s gastroezofagealnoj reflyuksnoj boleznyu. Gastroenterologiya Sankt-Peterburga. 2007; 1–2: 114. [in Russian]
13. Vasilev Yu.V., Masharova A.A., Yanova O.B. Gastroezofagealnaya reflyuksnaya bolezn, sochetayushayasya s hronicheskim pankreatitom i yazvennoj boleznyu. Kliniko-epidemiologicheskie i etno-ekologicheskie problemy zabolevanij organov pishevareniya. Krasnoyarsk, 2005; s. 18–9. [in Russian]
14. Xuan Jiang, Yan H, Peng X et al. Study on the characteristics of gastroesopheal reflux disease overlap with functional bowl diseases in Gl clinic. J Gastroenterol Hepatol 2013; 28 (Suppl. 3): 511.
15. Storonova O.A., Truhmanov A.S., Drapkina O.M., Ivashkin V.T. Ezofagogennye i koronarogennye boli v grudnoj kletke: problemy differencialnoj diagnostiki. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2002; 12 (1): 68–73. [in Russian]
16. Suhanova T.K., Ivahnenko O.M., Kovaleva N.A. Ekstrapishevodnye bronhopulmonalnye proyavleniya gastroezofagealnoj reflyuksnoj bolezni. Zdravoohranenie Dalnego Vostoka. 2002; 1: 280–9. [in Russian]
17. Kalyagin A.N. Kardialgicheskij H-sindrom. Sibirskij med. zhurn. (Irkutsk). 2001; 25 (2): 9–14. [in Russian]
18. Storonova O.A., Truhmanov A.S., Drapkina O.M., Ivashkin V.T. Ezofagogennye i koronarogennye boli v grudnoj kletke: problemy differencialnoj diagnostiki. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2002; 12 (1): 68–73. [in Russian]
19. Borjesson M, Albertsson P, Dellborg M et al. Esophageal dysfunction in Syndrome X. Am J Cardiol 1998; 82: 1187–92.
20. Ulabidin Z., Ivashkin V.T., Sheptulin A.A. i dr. Znachenie sutochnogo monitorirovaniya vnutripishevodnogo rN v diagnostike gastroezofagealnoj reflyuksnoj bolezni i ocenke effektivnosti lekarstvennyh preparatov. Klin. medicina. 1999; 7: 39. [in Russian]
21. Truhmanov A.C., Dzhahaya N.L., Kajbysheva V.O., Storonova O.A. Novye aspekty rekomendacij po lecheniyu bolnyh gastroezofagealnoj reflyuksnoj boleznyu. Gastroenterologiya i gepatologiya. 2013; 2: 2–9. [in Russian]
22. Hershcovici Т, Fass R. Gastro-oesophageal reflux disease: beyond proton pump inhibitor therapy. Drugs 2011; 71 (18): 2381–9.
23. Bordin D.S., Kolbasnikov S.V. Patogeneticheskie osnovy razvitiya gastroezofagealnoj reflyuksnoj bolezni. Diagnostika i lechenie. Vestn. semejnoj mediciny. 2013; 1: 30–4. [in Russian]
24. Kircheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors –comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19–31.
25. Sakai T, Aoyama N, Kita T et al. CYP 2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res 2001; 18 (6): 721–7.
26. Sychev DA, Denisenko NP, Sizova ZM et al. The frequency of CYP 2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med 2015; 27 (8): 111–4. DOI: 10.2147/ PGPM.S78986
27. Ivashkin V.T., Maev I.V., Ivashkin K.V. i dr. Rol narusheniya zashitnyh faktorov v razvitii kislotozavisimyh zabolevanij (rezolyuciya Ekspertnogo soveta 12–13 marta 2016 g.). Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2016; 26 (3): 115. [in Russian]
28. Skoczylas T, Sarosiek I, Sostarich S et al. Signicant enhancement of gastric mucin content after rabeprazole administration: its potential clinical signicance in acid-related disorders. Dig Dis Sci 2003; 48: 322–8.
29. Takiuchi H, Asada S, Umegaki E et al. Effects of proton pump inhibitors: omeprazole, lansoprazole, and E-3810 on the gastric mucin. 1994 (abstract).
30. Jaworski T, Sarosiek I, Sostarich S et al. Facg Restorative Impact of Rabeprazole on Gastric Mucus and Mucin Production Impairment During Naproxen Administration. Its Potent Clin Signific Digest Dis Sci 2005; 50 (2): 357–65.
31. Sarosiek I, Olyaee M, Majewski M et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential. Dig Dis Sci 2009; 54: 2137–42.
32. Okazaki M, Shimizu I, Ishikawa M et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. J Med Invest 2007; 54 (1–2): 83–90. DOI: 10.2152/jmi.54.83
33. Watanabe T, Higuchi K, Tominaga K et al. Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide: possible involvement of nitric oxide. Drug Exptl Clin Res 2000; 26 (2): 41–5.
34. Ivashkin V.T., Sheptulin A.A., Maev I.V. i dr. Klinicheskie rekomendacii Rossijskoj gastroenterologicheskoj associacii po diagnostike i lecheniyu erozivno-yazvennyh porazhenij zheludka i dvenadcatiperstnoj kishki, vyzvannyh nesteroidnymi protivovospalitelnymi preparatami. Ros. zhurn. gastroenterol., gepatol. i koloproktol. 2014; 6: 89–94. [in Russian].
35. Haastrup PF, Paulsen MS, Christensen RD et al. Medical and non-medical predictors of initiating long-term use of proton pump inhibitors: a nationwide cohort study of first-time users during a 10-year period. Aliment Pharmacol Ther 2016; 44 (1): 78–87.
36. Giuliano C, Wilhelm SM, Kale-Pradhan PB. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5 (3): 337–44.
37. Lewis PO, Litchfield JM, Tharp JL et al. Risk and Severity of Hospital-Acquired Clostridium difficile Infection in Patients Taking Proton Pump Inhibitors, 2016.
38. Niu Q, Wang Z, Zhang Y et al. Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. J Cardiovasc Pharmacol Ther 2016; pii: 1074248416663647.
39. Shulpekova Yu.O. primenenie rabeprazola v praktike gastroenterologa. Med. sovet. Gastroenterologiya. 2016; 14: 26–31. [in Russian]
40. Irani S, Krevsky B, Desipio J et al. Rapid protection of the gastroduodenal mucosa against aspirininduced damage by rabeprazole. Aliment Pharmacol Ther 2008; 27 (6): 498–503.
41. Karev E.N. Rabeprazol cherez prizmu «metabolizm-effektivnost». RMZh. 2016; s. 1172–6. [in Russian]
42. Uspenskij Yu.P., Pahomova I.G. Vybor ingibitorov protonnoj pompy u polimorbidnyh pacientov. Eksperiment. i klin. gastroenterologiya. 2013; 2: 65–72. [in Russian]
43. Zvenigorodskaya L.A., Churikova A.A. Gastroezofagealnaya reflyuksnaya bolezn u pozhilyh bolnyh. RMZh. 2011; 32: 2084. [in Russian]
44. Osadchuk M.A., Svistunov A.A, Osadchuk M.M., Nikolenko N.N. Gastroezofagealnaya reflyuksnaya bolezn kak multidisciplinarnaya patologiya. Poliklinika. 2013; 43: 88–96. [in Russian]
45. Eremina E.Yu. Taktika vedeniya pacienta s gastroezofagealnoj reflyuksnoj boleznyu. RMZh. 2017; 10: 707–10. [in Russian]
46. Pahomova I.G. Zinoveva E.N. Gastroezofagealnaya reflyuksnaya bolezn u polimorbidnogo pacienta: osobennosti terapii. RMZh. 2017; 10: 760–4. [in Russian]
47. Hlynov I.B., Chikunova M.V. Znachenie slizisto-bikarbonatnogo barera zheludka pri kislotozavisimyh zabolevaniyah. RMZh 2016; 17: 1125–9. [in Russian]
48. Fadeenko G.D. Vnepishevodnye proyavleniya gastroezofagealnoj reflyuksnoj bolezni. Zdorov’ya Ukrayini. 2006; 9: 26–7. [in Russian]

________________________________________________